Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-01-13 08:02 am Purchase | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Empery Asset Management, LP | 6,198,684 5.120% | 6,198,684 (New Position) | Filing History |
| 2022-12-19 5:31 pm Purchase | 2022-12-09 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE LLC | 12,136,793 9.990% | 5,258,636 (+76.45%) | Filing History |
| 2022-07-19 5:28 pm Purchase | 2022-07-06 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE LLC | 6,878,157 9.900% | 6,878,157 (New Position) | Filing History |
| 2022-02-14 4:43 pm Sale | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Ikarian Capital LLC | 2,264,491 8.100% | -360,497 (-13.73%) | Filing History |
| 2022-02-14 4:38 pm Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Point72 Asset Management, L.P. | 1,633,204 5.800% | 132,961 (+8.86%) | Filing History |
| 2022-02-14 4:11 pm Sale | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | RA Capital Management, L.P. | 1,136,000 3.900% | -612,021 (-35.01%) | Filing History |
| 2022-02-14 1:02 pm Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BIOTECHNOLOGY VALUE FUND L P | 3,027,672 9.990% | 1,308,056 (+76.07%) | Filing History |
| 2022-02-14 06:39 am Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BCLS I Investco, LP | 2,886,542 11.000% | 1,238,057 (+75.10%) | Filing History |
| 2022-02-11 5:08 pm Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 1,836,349 6.400% | 356 (+0.02%) | Filing History |
| 2022-02-11 3:17 pm Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | HIRSCHMAN ORIN | 1,531,600 6.200% | 72,700 (+4.98%) | Filing History |
| 2022-01-19 11:05 am Purchase | 2022-01-14 | 13G | X4 Pharmaceuticals, Inc. XFOR | Lincoln Park Capital Fund LLC | 1,810,087 6.440% | 1,810,087 (New Position) | Filing History |
| 2021-11-17 5:27 pm Purchase | 2021-11-09 | 13G | X4 Pharmaceuticals, Inc. XFOR | Point72 Asset Management, L.P. | 1,500,243 5.600% | 1,500,243 (New Position) | Filing History |
| 2021-06-28 7:32 pm Purchase | 2021-06-16 | 13G | X4 Pharmaceuticals, Inc. XFOR | HIRSCHMAN ORIN | 1,458,900 6.200% | 1,458,900 (New Position) | Filing History |
| 2021-05-07 5:09 pm Purchase | 2021-04-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | BlackRock Inc. BLK | 1,074,491 4.500% | 40,988 (+3.97%) | Filing History |
| 2021-04-08 09:02 am Purchase | 2021-03-23 | 13G | X4 Pharmaceuticals, Inc. XFOR | Ikarian Capital LLC | 2,624,988 11.100% | 1,798,564 (+217.63%) | Filing History |
| 2021-03-25 4:15 pm Purchase | 2021-03-23 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 1,835,993 7.600% | 587,000 (+47.00%) | Filing History |
| 2021-02-16 4:39 pm Purchase | 2020-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | RA Capital Management, L.P. | 1,748,021 9.900% | 99,536 (+6.04%) | Filing History |
| 2021-02-16 08:55 am Purchase | 2020-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Sphera Funds Management Ltd. | 250,000 1.510% | 250,000 (New Position) | Filing History |
| 2021-02-12 8:57 pm Purchase | 2020-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BIOTECHNOLOGY VALUE FUND L P | 1,719,616 9.990% | 59,141 (+3.56%) | Filing History |
| 2021-02-12 5:33 pm Sale | 2020-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | EcoR1 Capital LLC | 600,000 3.600% | -415,400 (-40.91%) | Filing History |